Published in:
Open Access
01-12-2023 | Computed Tomography | Research
The effect of biological agent on body composition in patients with Crohn’s disease
Authors:
Eun Jeong Choi, Dong Hoon Baek, Hong Sub Lee, Geun Am Song, Tae Oh Kim, Yong Eun Park, Chang Min Lee, Jong Hoon Lee, Busan Ulsan Gyeongnam Intestinal Study Group Society (BIGS)
Published in:
BMC Gastroenterology
|
Issue 1/2023
Login to get access
Abstract
Background
Crohn’s disease (CD) is associated with altered body composition, affecting clinical outcomes. We evaluated the impact of biologics on body composition in CD patients.
Methods
This multicenter longitudinal study across four Korean university hospitals conducted from January 2009 to August 2021 retrospectively reviewed data of CD patients with abdominal computed tomography (CT) before and after the biologic treatment. Skeletal muscle area (SMA), visceral fat area (VFA), and subcutaneous fat area (SFA) of the third lumbar vertebra (L3) on CT were measured. Myopenia was defined as L3 skeletal muscle index (SMI) of < 49 and < 31 cm2/m2 for men and women, respectively.
Results
Among 112 participants, 79 (70.5%) had myopenia. In the myopenia group, all body composition parameters were significantly increased after the biologic treatment: SMI (37.68 vs. 39.40 cm2/m2; P < 0.001), VFA (26.12 vs. 54.61 cm2; P < 0.001), SFA (44.29 vs. 82.42 cm2; P < 0.001), while no significant differences were observed in the non-myopenia group. In multivariate analysis, penetrating CD (hazard ratio, 5.40; P = 0.020) was the independent prognostic factor for surgery. Operation-free survival rate tended to decrease in the myopenia group (Log-rank test, P = 0.090).
Conclusions
Biological agents can increase all body composition parameters in CD patients with myopenia. These patients are more likely to experience surgery.